Ascendis Pharma AS (ASND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $18.06B
Last updated: Nov 17, 2026 at 4:23 PM ET
Ascendis Pharma AS (ASND) Statistics
Ascendis Pharma AS (ASND) has a market cap of $18.06B. Revenue grew 86.87% over the last 12 months from the 12 months before. Its share count is up 12.66% from a year earlier.
Total Valuation
| Market Cap | $18.06B |
|---|---|
| Latest price (Nov 17, 2026) | $271.19 |
Key Dates
The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 13.4x and 11.0x. Its year-end P/S ranged from 15.8x to 811.8x from 2016 to 2025.
| P/S Ratio | 13.4x |
|---|---|
| P/B Ratio | 11.0x |
| P/TBV Ratio | 11.0x |
| P/FCF Ratio | 31.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 60.7x EBITDA and 30.6x free cash flow.
| EV / EBITDA | 60.7x |
|---|---|
| EV / FCF | 30.6x |
Price Statistics
The stock is up 32.68% over 52 weeks and trades 11.73% above its 50-day average.
| Beta (1Y) | 0.44 |
|---|---|
| 52-Week Change | +32.68% |
| 1-Month Change | +17.93% |
| 3-Month Change | +4.46% |
| 6-Month Change | +13.96% |
| 5-Year Change | +65.73% |
| 10-Year Change | +1190.55% |
| Total Return (1Y) | +32.68% |
| Total Return (3Y CAGR) | +41.85% |
| Total Return (5Y CAGR) | +12.79% |
| Return vs SPY (1Y) | +13.34% |
| Max Drawdown (1Y) | -19.66% |
| Max Drawdown (3Y) | -29.15% |
| Sharpe Ratio (1Y) | 0.59 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $242.71 |
| 200-Day Average | $240.32 |
| 52-Week Range | $188.08 to $282.15 |
| RSI (14 Days) | 69.0 |
| Average Volume (20 Days) | 691.39K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.89x current liabilities, and total debt is 0.30x shareholder equity.
| Current Ratio | 2.89x |
|---|---|
| Quick Ratio | 2.29x |
| Debt / Equity | 0.30x |
| Debt / EBITDA | 1.71x |
| Interest Coverage | 1.52x |
Returns and Efficiency
Return on invested capital is 12.51% over the last 12 months, against a 5-year average of -34.08%.
| Return on Equity (ROE) | 60.22% |
|---|---|
| Return on Assets (ROA) | 37.23% |
| Return on Invested Capital (ROIC) | 12.51% |
| ROA (5Y Average) | -39.21% |
| ROIC (5Y Average) | -34.08% |
| Asset Turnover | 0.67x |
| Inventory Turnover | 0.36x |
| Receivables Turnover | 5.23x |
| Cash Conversion Cycle | 751 days |
Scores
ASND has an Altman Z-Score of 10.94, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 10.94 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was EUR 1.21B over the last 12 months.
| Revenue | EUR 1.21B |
|---|---|
| Revenue Growth (YoY) | +86.87% |
| Gross Profit | EUR 1.09B |
| Operating Income | EUR 222.29M |
| Pretax Income | EUR 271.18M |
| Net Income | EUR 890.37M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 61.73% of the EUR 2.43B in total assets.
| Working Capital | EUR 1.04B |
|---|---|
| Shareholder Equity | EUR 1.50B |
| Tangible Book Value | EUR 1.50B |
| Total Assets | EUR 2.43B |
| Total Liabilities | EUR 926.73M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After EUR 17.00M of capital spending, operating cash flow left EUR 516.87M of free cash flow.
| Operating Cash Flow | EUR 533.87M |
|---|---|
| Capital Expenditures | EUR 17.00M |
| Free Cash Flow | EUR 516.87M |
| Depreciation and Amortization | EUR 18.33M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 18.40%.
| Gross Margin | 90.61% |
|---|---|
| Operating Margin | 18.40% |
| Pretax Margin | 22.44% |
| Net Margin | 73.69% |
| FCF Margin | 42.78% |
| Gross Margin (5Y Average) | 77.45% |
Growth
Revenue grew 138.21% a year over 3 years.
| Revenue Growth (3Y CAGR) | +138.21% |
|---|---|
| Revenue Growth (5Y CAGR) | +150.93% |
Peer Position
Against 10 similar companies, ASND has the 6th highest P/S.
P/S RatioPeer median 12.1x
ROICPeer median 3.48%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +49.59%
| P/S Ratio | 13.4x vs 12.1x median |
|---|---|
| ROIC | 12.51% vs 3.48% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +86.87% vs +49.59% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ASND
What is ASND's market cap?
Ascendis Pharma AS has a market cap of $18.06B.
How many shares of ASND are outstanding?
Ascendis Pharma AS has 68.71M shares outstanding. The count is up 12.66% from a year earlier.
Does ASND pay a dividend?
No. Ascendis Pharma AS does not pay a dividend.
ASND pages: Overview, Charting, Financials, Statistics, Valuation, Competitors